Gemcitabine HCl: A Novel Anti-Cancer Drug

The global healthcare space has made phenomenal strides over the years, and cultural shifts, policy adjustments, and cost of care have contributed to a more patient-empowered shift in care delivery systems. As cancer is becoming one of the most expensive diseases to treat, the implementation of clinical pathways in oncology is gaining its very own eminence, which serves as an important tool in reducing variability in care delivery, improving outcomes, and controlling costs.

As several chemotherapy compounds have demonstrated activity against human malignancies, and fillings for Abbreviated New Drug Application (ANDA) have increased, the gemcitabine HCl market necessitates a thorough understanding and unbiased analysis. Transparency Market Research (TMR), in its new research study, brings to fore compelling insights and dynamic analysis to help its readers gain an in-depth understanding of the gemcitabine HCl market behavior in 2019 and beyond.

gemcitabine hci market strategy

Identify the key factors that will drive your company’s growth. Request a brochure of this report here 

Evolution and Future Prospects

The use of gemcitabine HCl has come a long way since it was studied in clinical trials during the early 1990s and approved for medical use in 1995. In view of its low-toxicity profile, gemcitabine HCl became an ideal candidate for the treatment of the ailing and elderly population suffering from advanced non small cell lung cancer (NSCLC). The worldwide sales of gemcitabine HCL closed in on US$ 500 million in 2018, and companies with a strong position in the market have gained the first-mover advantage. However, leading gemcitabine HCL market players are also put to test, as the significant rise in the demand for generic drugs has compelled the U.S. and European Union to update the import policies and legal cGMP requirements for API manufactures.

Generic Gemcitabine HCl Remains the Preferred Choice

The sales of generic cancer drugs are gaining strength in price-sensitive countries such as China, India, and Brazil, as the huge gap between the number of new cancer cases and cancer survivors initiates a surge in the acceptance of generic gemcitabine HCl. The year 2010 remains important in the context of generic versions of gemcitabine HCl; following the loss of exclusivity and patent expiry of 'Gemzar', a blockbuster branded gemcitabine drug of Eli Lily and Company, leading players are focusing on R&D investments and activities for these variants of cancer drugs. In addition, product innovation and strategies are highly influenced by the ease of developing generic formulations of gemcitabine HCl as compared to branded formulations; they are more rapid and exempted from the requirement to conduct clinical trials and toxicity studies. Therefore, leading market players are entering into manufacturing of generic drugs with cost-effective alternatives to branded products.

Innovations have also been forthcoming for combining the generic gemcitabine HCl with other compounds to enhance the treatment of several forms of cancer. Studies have found that, gemcitabine, in combination with nab-paclitaxe, results in prolonging the survival of patients suffering from metastatic pancreatic cancer.

gemcitabine hci market value share asia pacific analysis

Want to know more such detailed insights of Gemcitabine HCl market? Request a PDF sample here

Multimodal Approach to Lead the Gemcitabine HCl Market

Bolster the Sales Force with Multi-Channel Engagement

As competition in the gemcitabine HCl market intensifies, a strong product profile no longer suffices for building a distinctive brand persona. With the shift in purchasing power and reduced access to healthcare professionals (HCPs), pharmaceutical companies are being challenged to differentiate while adapting to the new rules of the market. The emergence of new digital channels brought significant changes among the leading gemcitabine market players in terms of maintaining HCP contact and increasing overall reach.

Investments in R&D Activities to Focus on Innovative Combined Products

R&D strategies in the gemcitabine HCl market, in the past few years, have been primarily focused on the improvement of treatment delivery and combination therapy. Sensing the unmet needs in the space and poor efficacy of the current treatments, key manufacturers have been prompted to explore and bring improved versions of branded gemcitabine agents into the market. These factors played an important role in Sun Pharma’s decision to launch ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in 2019, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation. This strategic move by Sun Pharma is highly likely to influence other stakeholders to invest in the R&D of combination therapy.

Expanding operations in future? To get the perfect launch ask for a custom report here

Focus on Lucrative Markets Such as India and China

Sensing the heavy investment scenario in the healthcare sector in developing countries such as India, China, and Singapore, key manufactures are targeting the expansion of their presence in these regions. India- and China-based companies also have a strong presence in the global gemcitabine HCl market, with a large number of gemcitabine API manufacturers in India investing to comply with U.S. FDA regulations, and file DMF applications.

The Competitive Landscape

The gemcitabine HCl market shows a high level of consolidation, with Eli Lily and Company, Teva Pharmaceuticals Industries Ltd., and Sun Pharmaceutical Industries Ltd. operating at the top of the market space.

Considering the nature of the product, maximization of drug potential and their commercialization continue to be influencing factors, and to stay competitive, many of these leading players are collaborating with important stakeholders in order to understand the challenges in developing effective gemcitabine HCl with minimum side effects. For instance, in 2018, Eli Liliy and Company collaborated with ARMO Biosciences Inc. to bolster Eli Liliy’s oncology program through the addition of ARMO's lead product candidate, pegilodecakin.

Strategic mergers and acquisitions to strengthen the therapeutic business and licensing agreements also remain a focus area of key manufacturers. In addition, as the importance of new product approval and commercialization intensifies, many players are entering into strategic partnerships and distribution agreements. It is highly likely that, companies such as Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., and Mylan N.V. will continue to emphasize on business partnerships to stay ahead of their competitors.

gemcitabine hci market segmentation

Analyst Viewpoint

As developing countries are investing in healthcare infrastructure to improve the quality of services and expand access, manufacturers will need to strengthen their marketing capabilities in these regions. With new updates and increasing stringency in regulatory standards, new collaborative models between pharmaceutical companies and research institutes will accelerate the development of new drugs and their approval processes.

Considering the poor efficacy of the current treatments for pancreatic cancer, the authors of this study feel that, along with price pressure and increased competition, key manufactures will need to dedicate their efforts toward developing cost-effective, reliable, and high-quality versions of gemcitabine HCl.

Global Gemcitabine HCl Market: Overview

  • Global gemcitabine HCl market size in 2018 – over US$ 500 Mn. The global gemcitabine HCl market is anticipated to grow at CAGR of nearly 7% during the forecast period.
  • The global gemcitabine HCl market report provides elaborative information and data analysis of the market with regards to segments based on application, type, end user, and geographical region.
  • The gemcitabine HCl market report provides detailed qualitative analysis with market forecast along with drivers, restrains and opportunities in the market. Additionally, the gemcitabine HCl market report also provides company profiles and competition matrix, which gives a brief idea about the business overview and competitive landscape of the gemcitabine HCl market.
  • The global gemcitabine HCl market report gives an idea about the market attractiveness of the industry in terms of particular segments and regions. It also gives provide quantitative and qualitative analysis on the market share of key players and competitive strategies adopted by them, by taking into account year-on year growth and market size.
  • Year on year growth rate of each segment of the global gemcitabine HCl market has been studied and analyzed after complete analysis of the demographics, patent expiry of branded drugs, past trends, regulatory trends, future trends, drug development lifecycle, etc. These key elements will help old as well as new players in the gemcitabine HCl market take strategic decisions in order reinforce their positions and multiply their share in the global gemcitabine HCl market.

Global Gemcitabine HCl Market: Key Segments

  • Based on type, the global gemcitabine HCl market has been segmented into branded and generic. In terms of application, the gemcitabine HCl market has been classified into pancreatic cancer, breast cancer, ovarian cancer, non-small-cell lung carcinoma (NSCLC), and others. Based on end user, the gemcitabine HCl market has been categorized into hospitals, cancer centers, and others.
  • By type, the global gemcitabine HCl market is expected to be dominated by generic drug manufactures, due to the patent expiry of branded drugs as well as increase in the demand for low-cost, efficient, and quality products. In terms of application, the global gemcitabine HCl market is predicted to be led by the pancreatic cancer segment, due to an increase in the number of pancreatic patients, as well as gemcitabine being considered as the 1st line of drug for the treatment of patients. By end user, the hospitals segment is expected to be a prominent segment in the global gemcitabine HCl market in the coming years.

Global Gemcitabine HCl Market: Regional Outlook

  • By geographical region, the global gemcitabine HCl market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region is further sub-divided into their respective countries.
  • The gemcitabine HCl market size and forecast of these regions/sub-regions/countries have been provided for the duration of 2019 to 2027. The CAGRs of the respective segments are also provided for the period of 2019 2027; here, 2018 has been considered as the base year.
  • North America, Europe, and Asia Pacific are predicted to have substantial shares as far as regional markets are concerned, in the global gemcitabine HCl market.
    • North America, Europe, and Asia Pacific are among the prominent markets, due to the patent expiry of Eli Lily’s branded drug Gemzar.
    • Asia Pacific and North America are large markets for gemcitabine HCl, owing to the favourable regulatory scenario for large molecule injectables (biosimilars), high demand for cost-effective generic formulations over branded ones, and government support to increase the utilization of generic injectable products, in these regions. A large number of manufacturers from emerging countries are targeting North America and Asia Pacific for launching generic injectable formulations, owing to injectable drug shortages being observed in these regions during the last decade. Patent expiry, increase in demand, and cost effectiveness are the key factors that are expected to drive the global gemcitabine HCl market.
    • Well-funded generic drug manufacturers are expected to exploit the growth outlook of the global gemcitabine HCl market. For example, gemcitabine API manufacturers in Asian countries such as India and China, who comply with U.S. FDA regulations, have been investing heavily in the generic drug sector. They have been filing Drug Master File (DMF) applications. Drug Master File (DMF) is a document that provides detailed information about the drug’s manufacturing facility, and the methods and processes used in the manufacturing, packaging, processing, and storage of drugs for humans. This scenario is expected to drive the global gemcitabine HCl market in the coming years.

Companies Mentioned in the Report

  • The gemcitabine HCl market report provides a complete analysis of the major players currently operating in the market. Additionally, the gemcitabine HCl market report also provides a brief analysis of the product portfolio, company overview, business strategies, and recent developments of the players.
  • Some of the companies profiled in the gemcitabine HCl market report are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., and Ingenus Pharmaceuticals.

Gemcitabine HCl Market: Report Description

A recent report published by Transparency Market Research analyzes the impact of past and present landscape on the future of the global gemcitabine HCl market. The study offers detailed information on the latest trends and opportunities for key stakeholders in the gemcitabine HCl market during the period of 2019-2027.

The report helps readers gauge the various dynamics of the gemcitabine HCl market, and provides actionable insights that can arm key stakeholders in the gemcitabine HCl market with the necessary information to take critical and well-informed decisions. TMR’s study also provides a key indicator analysis to define the growth prospects of the gemcitabine HCl market, and future estimates regarding the development of the gemcitabine HCl market in terms of value and volume.

The report provides exclusive data on the sales of gemcitabine HCl and the potential increase across different geographical regions. The study also includes thorough analysis of the existing competitive landscape, and offers detailed insights on product innovation and business development strategies adopted by key players in the gemcitabine HCl market.

Key Questions Answered in the Gemcitabine HCl Market Report

The report details a qualitative and quantitative breakdown of the gemcitabine HCl market, based on thorough research about the macro- and micro-economic aspects influencing the growth of the gemcitabine HCl market. Comprehensive information featured in the report can provide answers to various questions for industry participants, in order to enhance their decision-making processes. Some of these questions include:

  • How is the regulatory scenario in developed countries impacting the gemcitabine HCl market?
  • What are the potential threats faced by key stakeholders in the gemcitabine HCl market?
  • How will the historical prospects of the gemcitabine HCl market influence changes in the future?
  • What are the imperative strategies adopted by leading players to strengthen their position in the gemcitabine HCl market?
  • How will DMF fillings by India- and China-based companies influence the expansion of the gemcitabine HCl market?
  • What are the R&D strategies used by key manufactures to receive approval of their products?
  • What are the upcoming commercial prospects in the gemcitabine HCl market?

Gemcitabine HCl Market: Research Methodology

The research methodology followed by TMR’s analysts to obtain detailed information and estimate the overall size of the gemcitabine HCl market involves conducting thorough research. Industry-based information acquired through secondary resources are verified by conducting interviews with relevant stakeholders, which helped the analysts deliver extensive insights on how the gemcitabine HCl market will grow and expand during the course of the forecast period.

Around 34% of primary research for the development of the emcitabine HCl market report involved interviewing industry experts such as CEOs, presidents, directors, chairmen, vice presidents, and chief medical officers. Nearly 66% of primary respondents involved generic or branded medicine providers, scientists, physicians, oncology surgeons, healthcare professionals, surgeons, medical assistants, and assistant medical directors, along with product and brands managers of companies operating in the sales of gemcitabine HCl.

For secondary research, analysts have referred to company websites, white papers, annual reports, and financial report to confirm the accuracy of the future trends and opportunities of the gemcitabine HCl market. Other secondary resources include the Organization for Economic Co-operation and Development, Pubmed, Department of Health and Human Services, National Center for Health Statistics U.S., National Institute for Health and Clinical Excellence, and Association for Accessible Medicines.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Gemcitabine HCl Market: Segmentation

TMR’s report classifies the information into four broader categories – type, application, end user, and region. It include extensive assessment of the dynamics and evolving trends associated with each segment, and how they impact the overall growth of the gemcitabine HCl market.

The gemcitabine HCl market report covers all-inclusive information on the segment-wise trends and developments in the gemcitabine HCl market. Specific information includes y-o-y growth analysis, market value share comparison, pricing analysis, supply chain assessment, and attractiveness analysis on the basis of type, end user, and application across each key region

Type

Branded

Generic

Application

Pancreatic Cancer

Breast Cancer

Ovarian Cancer

Non-small-cell-lung Carcinoma (NSCLC)

Others

End User

Hospitals

Cancer Centers

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Global Gemcitabine HCL Market – Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology
    2.1. Gemcitabine HCL Market Definition
    2.2. Gemcitabine HCL Market Taxonomy

3. Executive Summary : Global Gemcitabine HCL Market
    3.1. Market Overview
    3.2. Introduction
    3.3. Type Definition
        3.3.1. Industry Evolution / Developments
    3.4. Overview
    3.5. Market Dynamics
        3.5.1. Drivers
        3.5.2. Restraints
        3.5.3. Opportunities
    3.6. Global Gemcitabine HCL Market Analysis and Forecast
        3.6.1. Market Revenue Projections (US$ Mn)
    3.7. Porter’s Five Force Analysis

4. Key Insights
    4.1. Disease Prevalence & Incidence Rate globally with key countries
    4.2. Regulatory Scenario by Region/globally
    4.3. Pipeline Analysis
    4.4. Key Mergers & Acquisitions
    4.5. Pricing Analysis of Finished products
    4.6. Overview of Manufacturers
    4.7. Consumption of Gemcitabine HCL(Volume) per Region (2018)
    4.8. Prices by Key Manufacturers(US$/kg)

5. Global Gemcitabine HCL Market Analysis and Forecast, By Type 
    5.1. Introduction
        5.1.1. Introduction & Definition By Type 
        5.1.2. Key Findings / Developments By Type 
    5.2. Market Size (US$ Mn) Forecast By Type 
        5.2.1. Branded 
        5.2.2. Generic 
    5.3. Market Attractiveness Analysis By Type 

6. Global Gemcitabine HCL Market Analysis and Forecast, By Application 
    6.1. Introduction
        6.1.1. Introduction & Definition By Application 
        6.1.2. Key Findings / Developments By Application 
    6.2. Market Size (US$ Mn) Forecast By Application 
        6.2.1. Pancreatic Cancer
        6.2.2. Breast Cancer
        6.2.3. Ovarian Cancer
        6.2.4. Non-small-cell Lung Carcinoma (NSCLC)
        6.2.5. Other

7. Global Gemcitabine HCL Market Analysis and Forecast, By End User 
    7.1. Introduction
        7.1.1. Introduction & Definition By End User 
        7.1.2. Key Findings / Developments By End User 
    7.2. Market Size (US$ Mn) Forecast By End User 
        7.2.1. Hospitals 
        7.2.2. Cancer Centers 
        7.2.3. Others  

8. Global Gemcitabine HCL Market Analysis and Forecast, By Region/sub-Region
    8.1. Introduction
        8.1.1. Introduction & Definition 
        8.1.2. Key Findings / Developments 
    8.2. Market Size (US$ Mn) Forecast By Region/Sub-Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific 
        8.2.4. Latin America
        8.2.5. Middle East and Africa (MEA)
    8.3. Market Attractiveness Analysis By Region/Sub-Region

9. North America Gemcitabine HCL Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Introduction & Definition 
        9.1.2. Key Findings / Developments 
    9.2. Market Size (US$ Mn) Forecast By Country
        9.2.1. U.S.
        9.2.2. Canada
    9.3. Market Size (US$ Mn) Forecast By Type 
        9.3.1. Branded 
        9.3.2. Generic 
    9.4. Market Size (US$ Mn) Forecast By Application 
        9.4.1. Pancreatic Cancer
        9.4.2. Breast Cancer
        9.4.3. Ovarian Cancer
        9.4.4. Non-small-cell Lung Carcinoma (NSCLC)
        9.4.5. Other
    9.5. Market Size (US$ Mn) Forecast By End User 
        9.5.1. Hospitals
        9.5.2. Cancer Centers 
        9.5.3. Others  
    9.6. Market Attractiveness Analysis
        9.6.1. By Country
        9.6.2. By Type 
        9.6.3. By Application 
        9.6.4. By End User 

10. Europe Gemcitabine HCL Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Introduction & Definition 
        10.1.2. Key Findings / Developments 
    10.2. Market Size (US$ Mn) and Forecast By Country /Sub-Region
        10.2.1. Germany
        10.2.2. France
        10.2.3. Italy
        10.2.4. Spain
        10.2.5. U.K.
        10.2.6. Rest of  Europe
    10.3. Market Size (US$ Mn) Forecast By Type 
        10.3.1. Branded 
        10.3.2. Generic 
    10.4. Market Size (US$ Mn) Forecast By Application 
        10.4.1. Pancreatic Cancer
        10.4.2. Breast Cancer
        10.4.3. Ovarian Cancer
        10.4.4. Non-small-cell Lung Carcinoma (NSCLC)
        10.4.5. Other
    10.5. Market Size (US$ Mn) Forecast By End User 
        10.5.1. Hospitals
        10.5.2. Cancer Centers 
        10.5.3. Others  
    10.6. Market Attractiveness Analysis
        10.6.1. By Country
        10.6.2. By Type 
        10.6.3. By Application 
        10.6.4. By End User 

11. Asia Pacific  Gemcitabine HCL Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Introduction & Definition 
        11.1.2. Key Findings / Developments 
    11.2. Market Size (US$ Mn) and Forecast By Country / Region
        11.2.1. China
        11.2.2. India
        11.2.3. Japan
        11.2.4. Australia and New Zealand
        11.2.5. Rest of Asia-Pacific
    11.3. Market Size (US$ Mn) Forecast By Type 
        11.3.1. Branded 
        11.3.2. Generic 
    11.4. Market Size (US$ Mn) Forecast By Application 
        11.4.1. Pancreatic Cancer
        11.4.2. Breast Cancer
        11.4.3. Ovarian Cancer
        11.4.4. Non-small-cell Lung Carcinoma (NSCLC)
        11.4.5. Other
    11.5. Market Size (US$ Mn) Forecast By End User 
        11.5.1.  Hospitals
        11.5.2. Cancer Centers 
        11.5.3. Others  
    11.6. Market Attractiveness Analysis
        11.6.1. By Country
        11.6.2. By Type 
        11.6.3. By Application 
        11.6.4. By End User 

12. Latin America Gemcitabine HCL Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Introduction & Definition 
        12.1.2. Key Findings / Developments 
    12.2. Market Size (US$ Mn) and Forecast By Country
        12.2.1. Brazil
        12.2.2. Mexico
        12.2.3. Rest of Latin America
    12.3. Market Size (US$ Mn) Forecast By Type 
        12.3.1. Branded 
        12.3.2. Generic 
    12.4. Market Size (US$ Mn) Forecast By Application 
        12.4.1. Pancreatic Cancer
        12.4.2. Breast Cancer
        12.4.3. Ovarian Cancer
        12.4.4. Non-small-cell Lung Carcinoma (NSCLC)
        12.4.5. Other
    12.5. Market Size (US$ Mn) Forecast By End User 
        12.5.1. Hospitals
        12.5.2. Cancer Centers 
        12.5.3. Others  
    12.6. Market Attractiveness Analysis
        12.6.1. By Country
        12.6.2. By Type 
        12.6.3. By Application 
        12.6.4. By End User 

13. MEA Gemcitabine HCL Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Introduction & Definition 
        13.1.2. Key Findings / Developments 
        13.1.3. Key Regulations
    13.2. Market Size (US$ Mn) Forecast By Country
        13.2.1. GCC Countries
        13.2.2. South Africa
        13.2.3. Rest of MEA
    13.3. Market Size (US$ Mn) Forecast By Type 
        13.3.1. Branded 
        13.3.2. Generic 
    13.4. Market Size (US$ Mn) Forecast By Application 
        13.4.1. Pancreatic Cancer
        13.4.2. Breast Cancer
        13.4.3. Ovarian Cancer
        13.4.4. Non-small-cell Lung Carcinoma (NSCLC)
        13.4.5. Other
    13.5. Market Size (US$ Mn) Forecast By End User 
        13.5.1. Hospitals
        13.5.2. Cancer Centers 
        13.5.3. Others  
    13.6. Market Attractiveness Analysis
        13.6.1. By Country
        13.6.2. By Type 
        13.6.3. By Application 
        13.6.4. By End User 

14. Competition Landscape
    14.1. Market Player - Competition Matrix 
    14.2. Market Share Analysis, by Company
        14.2.1. Eli Lilly and Company
        14.2.2. Teva Pharmaceutical Industries Ltd.
        14.2.3. Accord-UK Ltd.
        14.2.4. Pfizer, Inc.
        14.2.5. Mylan N.V.
        14.2.6. Sun Pharmaceutical Industries Ltd.
        14.2.7. Fresenius Kabi AG
        14.2.8. Dr. Reddy’s Laboratories Ltd.
        14.2.9. Ingenus Pharmaceuticals

List of Tables

Table 1: FDA Approved Drug Products 
Table 2: Pancreatic Cancer Promising Drugs in Clinical Development 
Table 3: Global Generic Products Sector Condition Overview
Table 4: Pricing Analysis of Finished Products
Table 5: USFDA Approved Gemcitabine HCL Manufacturers
Table 6: Europe Gemcitabine HCL Manufacturers
Table 7: India Gemcitabine HCL Manufacturers
Table 8: China Gemcitabine HCL Manufacturers
Table 9: Global Gemcitabine HCL Value (US$ Mn) Forecast, by Type, 2017–2027
Table 10: Global Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 11: Global Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 12: Global Gemcitabine HCL Value (US$ Mn) Forecast, by Region, 2017–2027
Table 13: North America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 14: North America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 15: North America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 16: North America Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 17: Europe Gemcitabine HCL Market Value (US$ Mn) Forecast, by Country/Region, 2017–2027
Table 18: Europe Gemcitabine HCL Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 19: Europe Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 20: Europe Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 21: Asia Pacific Gemcitabine HCL Market Value (US$ Mn) Forecast, by Country/Region, 2017–2027
Table 22: Asia Pacific Gemcitabine HCL Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 23: Asia Pacific Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 24: Asia Pacific Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 25: Latin America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 26: Latin America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 27: Latin America Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 28: Latin America Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 29: Middle East & Africa Gemcitabine HCL Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 30: Middle East & Africa Gemcitabine HCL Market Value (US$ Mn) Forecast, by Type , 2017–2027
Table 31: Middle East & Africa Gemcitabine HCL Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 32: Middle East & Africa Gemcitabine HCL Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

Figure 01: Global Gemcitabine HCL Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 02: Global Gemcitabine HCL Value Share, by Type, 2018
Figure 03: Global Gemcitabine HCL Value Share, by Application, 2018
Figure 04: Global Market Value Share, by End-user, 2018
Figure 05: Global Gemcitabine HCL Value Share, by Region, 2018
Figure 06: Global Gemcitabine HCL Value Share Analysis, by Type, 2019 and 2027
Figure 07: Global Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019 and 2027
Figure 08: Global Gemcitabine HCL Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017–2027
Figure 09: Global Gemcitabine HCL Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2027
 Figure 10: Global Gemcitabine HCL Market Value Share (%), by Application, 2019 and 2027
Figure 11: Global Gemcitabine HCL Market Attractiveness, by Application, 2019–2027
Figure 12: Global Gemcitabine HCL Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Pancreatic Cancer, 2017–2027
Figure 13: Global Gemcitabine HCL Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Breast Cancer, 2017–2027
Figure 14: Global Gemcitabine HCL Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ovarian Cancer , 2017–2027
Figure 15: Global Gemcitabine HCL Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Non-small-cell Lung Carcinoma (NSCLC) , 2017–2027
Figure 16: Global Gemcitabine HCL Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
Figure 17: Global Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 18: Global Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 19: Global Gemcitabine HCL Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals, 2017–2027
Figure 20: Global Gemcitabine HCL Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cancer Centers, 2017–2027
Figure 21: Global Gemcitabine HCL Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027
Figure 22: Global Gemcitabine HCL Market Value Share, by Region, 2019 and 2027
Figure 23 : Global Gemcitabine HCL Market Attractiveness, by Region, 2019–2027
Figure 24: North America Gemcitabine HCL Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 25: North America Gemcitabine HCL Market Value Share, by Country, 2019–2027
Figure 26: North America Gemcitabine HCL Market Attractiveness, by Country, 2019–2027
Figure 27: North America Gemcitabine HCL Market Value Share Analysis, by Type, 2019 and 2027
Figure 28: North America Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019–2027
Figure 29: North America Gemcitabine HCL Market Value Share Analysis, by Application, 2019 and 2027
Figure 30: North America Gemcitabine HCL Market Attractiveness Analysis, by Application, 2019–2027
Figure 31: North America Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 32: North America Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 33: Europe Gemcitabine HCL Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 34: Europe Gemcitabine HCL Market Value Share, by Country/Sub-region, 2019–2027
Figure 35: Europe Gemcitabine HCL Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 36: Europe Gemcitabine HCL Market Value Share Analysis, by Type, 2019 and 2027
Figure 37: Europe Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019–2027
Figure 38: Europe Gemcitabine HCL Market Value Share Analysis, by Application, 2019 and 2027
Figure 39: Europe Gemcitabine HCL Market Attractiveness Analysis, by Application, 2019–2027
Figure 40: Europe Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 41: Europe Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 42: Asia Pacific Gemcitabine HCL Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 43: Asia Pacific Gemcitabine HCL Market Value Share, by Country/Sub-region, 2019–2027
Figure 44: Asia Pacific Gemcitabine HCL Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 45: Asia Pacific Gemcitabine HCL Market Value Share Analysis, by Type, 2019 and 2027
Figure 46: Asia Pacific Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019–2027
Figure 47: Asia Pacific Gemcitabine HCL Market Value Share Analysis, by Application, 2019 and 2027
Figure 48: Asia Pacific Gemcitabine HCL Market Attractiveness Analysis, by Application, 2019–2027
Figure 49 : Asia Pacific Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 50 : Asia Pacific Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 51: Latin America Gemcitabine HCL Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 52: Latin America Gemcitabine HCL Market Value Share, by Country/Sub-region, 2019–2027
Figure 53: Latin America Gemcitabine HCL Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 54: Latin America Gemcitabine HCL Market Value Share Analysis, by Type, 2019 and 2027
Figure 55: Latin America Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019–2027
Figure 56: Latin America Gemcitabine HCL Market Value Share Analysis, by Application, 2019 and 2027
Figure 57: Latin America Gemcitabine HCL Market Attractiveness Analysis, by Application, 2019–2027
Figure 58: Latin America Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 59: Latin America Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 60: Middle East & Africa Gemcitabine HCL Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 61: Middle East & Africa Gemcitabine HCL Market Value Share, by Country/Sub-region, 2019–2027
Figure 62: Middle East & Africa Gemcitabine HCL Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 63: Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by Type, 2019 and 2027
Figure 64: Middle East & Africa Gemcitabine HCL Market Attractiveness Analysis, by Type, 2019–2027
Figure 65: Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by Application, 2019 and 2027
Figure 66: Middle East & Africa Gemcitabine HCL Market Attractiveness Analysis, by Application, 2019–2027
Figure 67: Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by End-user, 2019 and 2027
Figure 68: Middle East & Africa Gemcitabine HCL Market Attractiveness Analysis, by End-user, 2019–2027
Figure 69: Top Players operating in Market Space

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Gemcitabine Hcl Market